Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 9/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13280013 | 0.89 | EZH2 (0.50) | EZH2NOTUMCFTR | |
| SCHEMBL13280200 | 0.88 | EZH2 (0.47) | EZH2NOTUMATM | |
| SCHEMBL13279911 | 0.86 | EZH2 (0.49) | EZH2NOTUMKMT2ACFTRALDH1A1 | |
| SCHEMBL13280278 | 0.86 | EZH2 (0.46) | EZH2NOTUMCFTR | |
| SCHEMBL17004067 | 0.86 | EZH2 (0.46) | EZH2NOTUMKMT2A | |
| SCHEMBL18830061 | 0.86 | EZH2 (0.40) | EZH2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL15731229 | 0.85 | EZH2 (0.44) | EZH2NOTUMMEN1KMT2ACFTR | |
| SCHEMBL13280898 | 0.85 | EZH2 (0.44) | EZH2NOTUMKMT2ACFTRALDH1A1 | |
| SCHEMBL15731228 | 0.85 | EZH2 (0.44) | EZH2NOTUMMEN1KMT2ACFTR | |
| SCHEMBL13280264 | 0.85 | EZH2 (0.47) | EZH2MEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142083-A1 | Substituted Benzene Compounds | CYP1B1, TP53, VHL | EZH2 2519/4885NOTUM 478/4885MEN1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.